Why an inherited BRCA2 mutation changes prostate cancer screening for men

Men who inherit a pathogenic BRCA2 mutation develop prostate cancer earlier and in more dangerous forms than other men, and the largest dedicated screening study in carriers has now reported enough evidence to justify offering them systematic PSA testing [s1]. The picture for BRCA1 carriers is weaker: in the same study, their cancers looked no different from those of non-carriers after three years [s1].

BRCA1 and BRCA2 are best known for raising the risk of breast and ovarian cancer, and BRCA2 is also the strongest inherited driver of the rare cancers covered in male breast cancer. What is less widely understood is that the same genes bear on the commonest cancer in men. Both are tumour-suppressor genes whose normal job is repairing double-strand breaks in DNA; when a working copy is lost, cells accumulate damage, and in the prostate that shows up as cancer that arrives sooner and behaves worse.

The outcomes are worse, not just more common

The clearest evidence that a germline BRCA mutation changes the disease itself came from an analysis of 2,019 men with prostate cancer — 18 BRCA1 carriers, 61 BRCA2 carriers and 1,940 non-carriers [s2]. Tumours in carriers were more often high-grade (Gleason score of 8 or above, p=0.00003), more often locally advanced, and more often already spread to lymph nodes (p=0.00005) or distant sites (p=0.005) at diagnosis [s2]. Survival tracked those features: cancer-specific survival was 15.7 years in non-carriers versus 8.6 years in carriers, a difference that held after adjustment (hazard ratio 1.8, p=0.015) [s2]. Even among men whose cancer was localised at diagnosis, five-year cancer-specific survival was 96% in non-carriers against 82% in carriers, and metastasis-free survival 93% against 77% [s2]. The authors noted the worst outcomes clustered in BRCA2 carriers; the BRCA1 subgroup was too small to draw firm conclusions [s2].

What screening in carriers actually found

The IMPACT study set out to test whether PSA screening earns its place in this group. It recruited 3,027 men aged 40 to 69 — 919 BRCA1 carriers, 709 BRCA1 non-carriers, 902 BRCA2 carriers and 497 BRCA2 non-carriers — and offered a prostate biopsy to anyone whose PSA rose above 3.0 ng/ml [s1]. After three years, 527 men had a PSA above that threshold, 357 biopsies were done, and 112 cancers were found [s1].

The signal was specific to BRCA2. Cancer incidence was 19.4 per 1,000 person-years in BRCA2 carriers versus 12.0 in non-carriers (p=0.03); carriers were diagnosed younger (median 61 versus 64 years, p=0.04); and their tumours were far more likely to be clinically significant — 77% versus 40% (p=0.01) [s1]. In other words, PSA screening in BRCA2 carriers was not just catching more cancer, it was catching more of the cancer that matters. No such difference appeared between BRCA1 carriers and non-carriers on any measure, which is why the study's authors recommended systematic PSA screening for BRCA2 carriers while calling for longer follow-up before extending the same advice to BRCA1 [s1].

That is a meaningful caveat in a field where PSA screening is otherwise contested precisely because it detects many cancers that would never have caused harm. Concentrating screening on men whose inherited risk skews toward aggressive disease is a more favourable trade than population-wide testing, and it pairs naturally with an MRI-first diagnostic pathway designed to separate dangerous tumours from indolent ones.

Genetics also points to treatment

Knowing a man's BRCA status is not only a screening question; it now changes what can be offered if the cancer spreads. The PROfound trial randomised men with metastatic castration-resistant prostate cancer and DNA-repair gene alterations to the PARP inhibitor olaparib or a further hormonal drug [s3]. In the group with BRCA1, BRCA2 or ATM alterations (245 men), imaging-based progression-free survival was 7.4 months with olaparib versus 3.6 months with the control (hazard ratio 0.34, 95% CI 0.25 to 0.47; P<0.001), and median overall survival was 18.5 versus 15.1 months despite 81% of the control group later crossing over to olaparib [s3]. PARP inhibitors exploit the same repair defect the mutation creates — a tumour that cannot fix double-strand breaks is unusually vulnerable to a drug that blocks its backup repair pathway.

Who this applies to, and what is still uncertain

A 2017 multidisciplinary consensus conference reached strong agreement that men should make genetic-testing decisions through shared decision-making, that BRCA2 status should be factored into prostate-cancer screening discussions, and that all men with metastatic castration-resistant disease should be tested for BRCA1/2 and ATM regardless of family history, to inform prognosis and targeted therapy [s4]. It reached only moderate agreement on how heavily to weight BRCA2 in early-stage management [s4].

The limits are worth stating plainly. IMPACT's screening findings are interim, from three years of follow-up, and its verdict on BRCA1 is "not yet," not "no" [s1]. The survival data in carriers come from observational cohorts, not randomised comparisons, so they describe how the disease behaves rather than proving that earlier detection changes the outcome [s2]. And none of this speaks to the large majority of prostate cancer, which arises in men with no identified inherited mutation — a reminder that the survival differences between standard treatments remain the central question for most patients, and that screening decisions still turn on weighing overdiagnosis against benefit. What genetics adds is a way to find the men for whom that balance tips clearly toward screening.